COMPOSITIONS COMPRISING MEAI AND N-ACYLETHANOLAMINES AND USES THEREOF

1 . A pharmaceutical composition comprising 5-methoxy-2-aminoindan or a salt thereof, and an N-acylethanolamine or a salt thereof; and at least one pharmaceutically acceptable carrier and/or excipient.

2 . The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is a unit dosage form composition.

3 . The pharmaceutical composition of claim 2 , wherein the pharmaceutical composition is a solid unit dosage form composition or a liquid unit dosage form composition.

4 . (canceled)

5 . The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is packaged as a single unit dose or as a plurality of single unit doses.

6 . The pharmaceutical composition of claim 2 , wherein the unit dosage form composition comprises from 30 mg to 130 mg of 5-methoxy-2-aminoindan.

7 . The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is formulated for oral administration.

8 - 17 . (canceled)

18 . The pharmaceutical composition of claim 1 , wherein the 5-methoxy-2-aminoindan or salt thereof and the N-acylethanolamine or salt thereof is present in a molar ratio from about 1:0.2 to about 1:2000.

19 . The pharmaceutical composition of claim 6 , wherein the unit dosage form composition comprises about 70 mg of the 5-methoxy-2-aminoindan or salt thereof.

20 . The pharmaceutical composition of claim 1 , comprising:

a) about 200 mg to 1800 mg of the N-acylethanolamine or salt thereof;

b) about 250 mg to 1550 mg of the N-acylethanolamine or salt thereof;

c) about 300 mg to 1200 mg of the N-acylethanolamine or salt thereof;

d) about 350 mg to 950 mg of the N-acylethanolamine or salt thereof;

e) about 400 mg to 700 mg of the N-acylethanolamine or salt thereof; or

f) about 450 mg to 600 mg of the N-acylethanolamine or salt thereof.

21 . The pharmaceutical composition of claim 1 , comprising:

a) about 50 mg of the N-acylethanolamine or salt thereof;

b) about 100 mg of the N-acylethanolamine or salt thereof;

c) about 150 mg of the N-acylethanolamine or salt thereof;

d) about 200 mg of the N-acylethanolamine or salt thereof;

e) about 250 mg of the N-acylethanolamine or salt thereof;

f) about 400 mg of the N-acylethanolamine or salt thereof;

g) about 500 mg of the N-acylethanolamine or salt thereof;

h) about 750 mg of the N-acylethanolamine or salt thereof;

i) about 800 mg of the N-acylethanolamine or salt thereof;

j) about 1000 mg of the N-acylethanolamine or salt thereof; or

k) about 1500 mg of the N-acylethanolamine or salt thereof.

22 . The pharmaceutical composition of claim 1 , wherein the N-acylethanolamine or salt thereof is selected from N-palmitoylethanolamine (PEA), Me-palmitoylethanolamide (Me-PEA), palmitoylcyclohexamide, palmitoylbutylamide, oleoylethanolamine (OEA), palmitoylisopropylamide (PIA), and any combination thereof.

23 . The pharmaceutical composition of claim 1 , wherein the N-acylethanolamine or salt thereof comprises N-palmitoylethanolamine (PEA).

24 . A method of regulating binge behavior, comprising administering to a subject in need thereof a therapeutically effective amount of 5-methoxy-2-aminoindan or a salt thereof, and a therapeutically effective amount of an N-acylethanolamine or a salt thereof.

25 . The method of claim 24 , wherein the binge behavior is associated with alcohol consumption, eating, tobacco consumption, shopping, or sexual conduct.

26 . The method of claim 24 , wherein the binge behavior is binge drinking.

27 . The method of claim 24 , wherein the therapeutically effective amount of the 5-methoxy-2-aminoindan or salt thereof comprises from 30 mg to 130 mg of 5-methoxy-2-aminoindan.

28 . The method of claim 24 , wherein the therapeutically effective amount of the N-acylethanolamine or salt thereof comprises:

a) about 200 mg to 1800 mg of the N-acylethanolamine or salt thereof;

b) about 250 mg to 1550 mg of the N-acylethanolamine or salt thereof;

c) about 300 mg to 1200 mg of the N-acylethanolamine or salt thereof;

d) about 350 mg to 950 mg of the N-acylethanolamine or salt thereof;

e) about 400 mg to 700 mg of the N-acylethanolamine or salt thereof; or

f) about 450 mg to 600 mg of the N-acylethanolamine or salt thereof.

29 . The method of claim 24 , wherein the therapeutically effective amount of the N-acylethanolamine or salt thereof comprises:

a) about 50 mg of the N-acylethanolamine or salt thereof;

b) about 100 mg of the N-acylethanolamine or salt thereof;

c) about 150 mg of the N-acylethanolamine or salt thereof;

d) about 200 mg of the N-acylethanolamine or salt thereof;

e) about 250 mg of the N-acylethanolamine or salt thereof;

f) about 400 mg of the N-acylethanolamine or salt thereof;

g) about 500 mg of the N-acylethanolamine or salt thereof;

h) about 750 mg of the N-acylethanolamine or salt thereof;

i) about 800 mg of the N-acylethanolamine or salt thereof;

j) about 1000 mg of the N-acylethanolamine or salt thereof; or

k) about 1500 mg of the N-acylethanolamine or salt thereof.

30 . The method of claim 24 , wherein the N-acylethanolamine or salt thereof is selected from N-palmitoylethanolamine (PEA), Me-palmitoylethanolamide (Me-PEA), palmitoylcyclohexamide, palmitoylbutylamide, oleoylethanolamine (OEA), palmitoylisopropylamide (PIA), and any combination thereof.

31 . The method of claim 24 , wherein the N-acylethanolamine or salt thereof comprises N-palmitoylethanolamine (PEA).

32 . The method of claim 24 , wherein the therapeutically effective amount of the 5-methoxy-2-aminoindan or salt thereof and the therapeutically effective amount of the N-acylethanolamine or salt thereof are formulated in the pharmaceutical composition of claim 1 .

33 . A method of regulating alcohol consumption, comprising administering to a subject in need thereof the pharmaceutical composition of claim 1 .

34 . A method of increasing a preference for consuming water compared to consuming alcohol, comprising administering to a subject in need thereof the pharmaceutical composition of claim 1 .

35 . A method of increasing water consumption in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of 5-methoxy-2-aminoindan or a salt thereof.

36 . A method of increasing water consumption in a subject, comprising administering to a subject in need thereof the pharmaceutical composition of claim 1 .

37 . A method of increasing a preference for consuming water compared to consuming alcohol, comprising administering to a subject in need thereof a therapeutically effective amount of 5-methoxy-2-aminoindan or a salt thereof.